InspireMD's Mguard embolic protection stent has demonstrated a positive outcome in treating patients suffering heart attacks when compared to bare metal or drug-eluting stents during the study.
The multi-center randomized MASTER (MGuard for Acute ST Elevation Reperfusion) trial has enrolled 433 patients across nine countries to evaluate the Mguard stent compared to commercially-approved bare metal or drug-eluting stents.
The Mguard embolic protection stent is a coronary stent integrated with a proprietary micronet technology that is designed to hold plaque and thrombus in place against the blocked artery’s wall.
InspireMD chief executive officer Ofir Paz said the company hase reached a milestone in the history of InspireMD.
"We look forward to presenting detailed results of the MGuard™ MASTER trial at the TCT in October," Paz added.